Status:
RECRUITING
Thromboembolic Risk Assessment in Patients Admitted With Acute Medical Diseases to Conventional and At Home Hospitalization
Lead Sponsor:
Universidad Pública de Navarra
Collaborating Sponsors:
Sociedad Española De Medicina Interna
Daiichi Sankyo
Conditions:
Thromboprophylaxis
Thromboembolism, Venous
Eligibility:
All Genders
18+ years
Brief Summary
The thromboembolic disease is a common complication of patients admitted to conventional hospitalization units. To prevent such complications, thromboprophylaxis is indicated in high-risk patients ide...
Detailed Description
1953 patients will be recruited (1700 in at home hospitalization units and 253 in conventional hospitalization units). All patients must accept and sign the informed consent. After being admitted to t...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Patients admitted with acute medical diseases to either a conventional hospitalization unit or at home hospitalization units
- Capable and willing to provide an informed consent
Exclusion
- End of life disease, palliative care or with an expected survival inferior to 3 months
- Patients receiving therapeutic doses of any anticoagulant drug
- Active diagnosis of thromboembolic disease
- Prior diagnosis of atrial fibrillation
- Pregnancy or breast-feeding.
- SARS-CoV-2 diagnosed using real-time reverse transcriptase polymerase chain reaction (PCR) tests or positive for SARS-CoV-2 virus antigen \<90 days before randomization.
Key Trial Info
Start Date :
March 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
1953 Patients enrolled
Trial Details
Trial ID
NCT06110949
Start Date
March 1 2023
End Date
March 1 2025
Last Update
May 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario de Navarra
Pamplona, Navarre, Spain, 31008